Cargando…

Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping

BACKGROUND: Axillary reverse mapping (ARM) is a new technique developed with the aim of reducing lymphedema rates by preserving lymphatic drainage of the upper limbs during sentinel lymph node biopsy and axillary lymph node dissection (ALND). However, it is unclear whether preservation of these lymp...

Descripción completa

Detalles Bibliográficos
Autores principales: Schunemann, Eduardo, Dória, Maíra Teixeira, Silvestre, Janiceli Blanca Carlotto Hablich, Gasperin, Plínio, Cavalcanti, Teresa Cristina Santos, Budel, Vinicius Milani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047480/
https://www.ncbi.nlm.nih.gov/pubmed/24599413
http://dx.doi.org/10.1245/s10434-014-3626-5
_version_ 1782480403289866240
author Schunemann, Eduardo
Dória, Maíra Teixeira
Silvestre, Janiceli Blanca Carlotto Hablich
Gasperin, Plínio
Cavalcanti, Teresa Cristina Santos
Budel, Vinicius Milani
author_facet Schunemann, Eduardo
Dória, Maíra Teixeira
Silvestre, Janiceli Blanca Carlotto Hablich
Gasperin, Plínio
Cavalcanti, Teresa Cristina Santos
Budel, Vinicius Milani
author_sort Schunemann, Eduardo
collection PubMed
description BACKGROUND: Axillary reverse mapping (ARM) is a new technique developed with the aim of reducing lymphedema rates by preserving lymphatic drainage of the upper limbs during sentinel lymph node biopsy and axillary lymph node dissection (ALND). However, it is unclear whether preservation of these lymph nodes affects oncological risk. The present study evaluated the presence of metastases in ARM nodes. METHODS: A total of 45 patients underwent ARM during ALND. Blue dye was used for ARM nodes localization. All axillary lymph nodes, including ARM nodes, were removed and sent separately for pathological evaluation of metastases. RESULTS: ARM identification was achieved in 40/45 patients (88.9 %). The average number of removed ARM nodes was 1.9. ARM nodes metastasis occurred in 10 of 40 patients (25 %). Patients with an axilla extensively affected by cancer had an elevated risk of metastasis to the arm’s lymph nodes (p < 0.001). CONCLUSIONS: The rate of arm lymph nodes compromised by metastases calls into question the viability of the ARM technique. Larger studies may point to particular patient profiles for which ARM can be safely use.
format Online
Article
Text
id pubmed-4047480
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-40474802014-06-09 Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping Schunemann, Eduardo Dória, Maíra Teixeira Silvestre, Janiceli Blanca Carlotto Hablich Gasperin, Plínio Cavalcanti, Teresa Cristina Santos Budel, Vinicius Milani Ann Surg Oncol Breast Oncology BACKGROUND: Axillary reverse mapping (ARM) is a new technique developed with the aim of reducing lymphedema rates by preserving lymphatic drainage of the upper limbs during sentinel lymph node biopsy and axillary lymph node dissection (ALND). However, it is unclear whether preservation of these lymph nodes affects oncological risk. The present study evaluated the presence of metastases in ARM nodes. METHODS: A total of 45 patients underwent ARM during ALND. Blue dye was used for ARM nodes localization. All axillary lymph nodes, including ARM nodes, were removed and sent separately for pathological evaluation of metastases. RESULTS: ARM identification was achieved in 40/45 patients (88.9 %). The average number of removed ARM nodes was 1.9. ARM nodes metastasis occurred in 10 of 40 patients (25 %). Patients with an axilla extensively affected by cancer had an elevated risk of metastasis to the arm’s lymph nodes (p < 0.001). CONCLUSIONS: The rate of arm lymph nodes compromised by metastases calls into question the viability of the ARM technique. Larger studies may point to particular patient profiles for which ARM can be safely use. Springer US 2014-03-06 2014 /pmc/articles/PMC4047480/ /pubmed/24599413 http://dx.doi.org/10.1245/s10434-014-3626-5 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Breast Oncology
Schunemann, Eduardo
Dória, Maíra Teixeira
Silvestre, Janiceli Blanca Carlotto Hablich
Gasperin, Plínio
Cavalcanti, Teresa Cristina Santos
Budel, Vinicius Milani
Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping
title Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping
title_full Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping
title_fullStr Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping
title_full_unstemmed Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping
title_short Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping
title_sort prospective study evaluating oncological safety of axillary reverse mapping
topic Breast Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047480/
https://www.ncbi.nlm.nih.gov/pubmed/24599413
http://dx.doi.org/10.1245/s10434-014-3626-5
work_keys_str_mv AT schunemanneduardo prospectivestudyevaluatingoncologicalsafetyofaxillaryreversemapping
AT doriamairateixeira prospectivestudyevaluatingoncologicalsafetyofaxillaryreversemapping
AT silvestrejaniceliblancacarlottohablich prospectivestudyevaluatingoncologicalsafetyofaxillaryreversemapping
AT gasperinplinio prospectivestudyevaluatingoncologicalsafetyofaxillaryreversemapping
AT cavalcantiteresacristinasantos prospectivestudyevaluatingoncologicalsafetyofaxillaryreversemapping
AT budelviniciusmilani prospectivestudyevaluatingoncologicalsafetyofaxillaryreversemapping